Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (AML). Here we report an independent review of EFS,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Haematologica
Hlavní autoři: Lambert, Juliette, Pautas, Cécile, Terré, Christine, Raffoux, Emmanuel, Turlure, Pascal, Caillot, Denis, Legrand, Ollivier, Thomas, Xavier, Gardin, Claude, Gogat-Marchant, Karïn, Rubin, Stephen D., Benner, Rebecca J., Bousset, Pierre, Preudhomme, Claude, Chevret, Sylvie, Dombret, Herve, Castaigne, Sylvie
Médium: Artigo
Jazyk:Inglês
Vydáno: Ferrata Storti Foundation 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6312010/
https://ncbi.nlm.nih.gov/pubmed/30076173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.188888
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky